

## **Human Duchenne Muscular Dystrophy (DMD) Treatment Market Report and Forecast 2024-2032**

Market Report | 2024-09-30 | 250 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

### **Report description:**

Duchenne Muscular Dystrophy (DMD) Treatment Market Report and Forecast 2024-2032??

The duchenne muscular dystrophy (DMD) treatment market attained a value of nearly USD 1.5 billion in 2023. The market is estimated to grow at a CAGR of approximately 12.50% during the period 2024-2032, reaching about USD 4.22 billion by 2032. This growth is driven by advancements in treatment options, increased awareness of duchenne muscular dystrophy, and ongoing research and development initiatives, alongside supportive government policies and funding.

### Duchenne Muscular Dystrophy (DMD) Treatment Market- Analysis

Human duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. The treatment landscape for DMD is evolving rapidly, with significant advancements in molecular-based therapies, gene therapy, and steroid treatments. The market focuses on developing innovative therapeutic approaches to slow disease progression, manage symptoms, and improve the quality of life for patients. Increased awareness, government initiatives, and ongoing research and development are driving substantial growth in this market. Effective duchenne muscular dystrophy treatment requires a multidisciplinary approach, combining medical, physical, and supportive therapies to address the complex needs of patients.

### Market Driver

Technological Advancements: Continuous innovation in medical technology has significantly enhanced the treatment landscape for duchenne muscular dystrophy. Advanced gene therapies, molecular-based treatments, and improved drug formulations are

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

driving market growth by offering more effective and targeted treatment options. Innovations in delivery mechanisms, such as nanoparticle-based systems, and enhanced formulations are improving patient outcomes. Additionally, advancements in telemedicine and digital health platforms facilitate remote monitoring and management of DMD, ensuring comprehensive care and support.

**Increased Awareness and Diagnosis:** Rising awareness about duchenne muscular dystrophy among healthcare providers and the public is leading to earlier diagnosis and intervention. Educational campaigns, patient advocacy groups, and media coverage are pivotal in promoting timely treatment and improving patient outcomes. Increased awareness encourages early genetic testing and screening, enabling prompt initiation of therapies that can slow disease progression and enhance quality of life.

**Government Support and Funding:** Government initiatives and funding are playing a pivotal role in advancing duchenne muscular dystrophy research and treatment. Financial support for clinical trials, research programs, and healthcare infrastructure improvements is boosting market growth. Policies promoting rare disease research and subsidies for treatment costs help make advanced therapies more accessible. Collaboration between government agencies and pharmaceutical companies accelerates the development and approval of new treatments, expanding the therapeutic options available to patients.

**R&D Initiatives:** Ongoing research and development activities are leading to the discovery of novel therapies and drugs for duchenne muscular dystrophy. Collaboration between academic institutions, research organizations, and pharmaceutical companies is accelerating the development of innovative treatment options. Significant R&D investments are resulting in breakthroughs in gene editing, exon-skipping therapies, and other advanced techniques. These efforts are aimed at addressing the underlying genetic causes of DMD, offering hope for more effective and long-lasting treatments.

## Market Challenges

**High Treatment Costs:** The cost of duchenne muscular dystrophy treatments, including advanced therapies and supportive care, can be prohibitively high. This financial burden limits access to treatment for many patients, especially in low-income regions, posing a significant challenge to market growth. High costs associated with gene therapies, long-term steroid use, and supportive treatments require substantial financial resources, making affordability a major barrier.

**Limited Availability of Treatments:** Despite advancements, the availability of effective duchenne muscular dystrophy treatments remains limited. Regulatory hurdles, long approval processes, and manufacturing challenges contribute to the restricted availability of novel therapies. These barriers delay the introduction of new treatments to the market, affecting patient access to cutting-edge care.

**Disease Complexity:** The complex nature of duchenne muscular dystrophy, involving multiple genetic mutations and varying disease progression, makes treatment development challenging. Tailoring therapies to individual patients' needs is difficult, hindering the efficacy of treatments. The heterogeneity of the disease requires personalized approaches, complicating clinical trial designs and regulatory approvals.

**Patient Compliance:** Ensuring patient adherence to treatment regimens is a significant challenge. The demanding nature of duchenne muscular dystrophy treatments, including frequent hospital visits and rigorous medication schedules, can lead to poor compliance and suboptimal outcomes. Addressing issues related to the burden of treatment and improving patient education is crucial for better adherence.

## Future Opportunities

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Emerging Markets:** Expanding into emerging markets with improving healthcare infrastructure offers substantial growth opportunities. These regions present untapped potential for increasing access to DMD treatments and improving patient outcomes. Rising healthcare investments and government initiatives in countries like India and China are expected to drive market growth.

**Personalised Medicine:** The development of personalized medicine approaches tailored to individual genetic profiles holds promise for improving DMD treatment efficacy. Advances in genetic testing and biomarkers are paving the way for customized therapies. Personalized treatments can enhance therapeutic outcomes by targeting the specific mutations and disease mechanisms in each patient.

**Innovative Drug Delivery Systems:** Developing new drug delivery systems, such as long-acting injectables and oral formulations, can enhance patient compliance and treatment effectiveness. These innovations can simplify administration and improve the quality of life for patients. Innovative delivery methods, such as gene editing technologies, also offer the potential for more precise and less invasive treatments.

**Collaborative Research Initiatives:** Increased collaboration between pharmaceutical companies, research institutions, and healthcare providers can drive innovation and accelerate the development of new treatments. Collaborative efforts can pool resources and expertise, fostering breakthroughs in DMD therapy. Public-private partnerships and global research networks are crucial for advancing DMD treatment.

#### Duchenne Muscular Dystrophy (DMD) Treatment Market Trends

**Gene Therapy Advancements:** The advancement of gene therapy is revolutionizing DMD treatment. Therapies targeting the underlying genetic causes of DMD are showing promise in clinical trials, offering hope for more effective and lasting treatments. Innovations in gene editing and delivery technologies are expected to drive market growth.

**Focus on Early Intervention:** There is a growing emphasis on early intervention in DMD treatment. Early diagnosis and initiation of therapy can slow disease progression and improve long-term outcomes, driving the adoption of screening programs and early treatment strategies. Early intervention efforts are supported by increased awareness and improved diagnostic technologies.

**Increased Investment in R&D:** Investment in research and development for DMD treatments is on the rise. Pharmaceutical companies and research institutions are dedicating significant resources to discovering new therapies and improving existing ones. Increased funding for DMD research is accelerating the development of innovative treatments and expanding therapeutic options.

**Patient-Centric Care Models:** The shift towards patient-centric care models is influencing DMD treatment. Integrating multidisciplinary care teams and personalized treatment plans is enhancing the quality of care and patient satisfaction, supporting market growth. Patient-centric approaches focus on holistic care, addressing not only medical needs but also the psychological and social aspects of living with DMD.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Duchenne Muscular Dystrophy (DMD) Treatment Market Segmentation

### Market Breakup by Therapeutic Approaches

Molecular-based Therapies

Mutation Suppression

Exon Skipping

Steroid Therapy

Other Therapeutic Approaches

The human duchenne muscular dystrophy treatment market is segmented by therapeutic approaches, including molecular-based therapies, steroid therapy, and other therapeutic approaches. Molecular-based therapies, such as mutation suppression and exon skipping, are at the forefront of innovation, offering targeted treatment options. Steroid therapy remains a mainstay in managing symptoms and slowing disease progression. Other therapeutic approaches, including physical therapy and supportive care, complement medical treatments by improving patient mobility and quality of life. These segments collectively drive market growth by providing a comprehensive approach to managing DMD.

### Market Breakup by Distribution Channel

Hospitals

Retail and Online Pharmacies

The market is segmented by distribution channel into hospitals, retail, and online pharmacies. Hospitals play a critical role in providing specialized care and administering advanced treatments for DMD. Retail and online pharmacies ensure the availability of medications and support ongoing treatment regimens. The accessibility of these channels facilitates continuous care and adherence to prescribed therapies, contributing to market expansion.

### Market Breakup by End User

Hospitals

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Home Care Settings

## Clinics

The market is segmented by end user into hospitals, home care settings, and clinics. Hospitals and clinics are essential for diagnosing and initiating treatment plans, offering specialized care, and monitoring. Home care settings are increasingly important for managing long-term care, providing convenience, and improving the quality of life for patients. This segmentation reflects the diverse settings in which DMD treatment is administered, each playing a crucial role in patient management and support.

## Market Breakup by Region

### United States

### EU-4 and the United Kingdom

#### Germany

#### France

#### Italy

#### Spain

#### United Kingdom

#### Japan

#### India

The human duchenne muscular dystrophy treatment market is segmented by region into the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. The United States and EU-4 lead the market due to advanced healthcare infrastructure and high research activity. Japan and India are emerging markets with growing healthcare investments and increasing awareness of DMD. These regions are expected to drive market growth through improved access to treatments and supportive government policies.

## Duchenne Muscular Dystrophy (DMD) Treatment Market Competitive Landscape

The human duchenne muscular dystrophy treatment market features several key players actively shaping the competitive landscape. Notable companies include Pfizer Inc., Sarepta Therapeutics, Inc., PTC Therapeutics Inc., FibroGen, Inc., F. Hoffmann-La Roche Ltd, NS Pharma, Inc., Solid Biosciences Inc., Nippon Shinyaku Co., Ltd, and Italfarmaco SpA. These companies engage in activities such as mergers and acquisitions, research initiatives, product introductions, and strategic partnerships to expand their

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

market presence and capabilities. These activities drive innovation and growth within the human duchenne muscular dystrophy treatment market, ensuring continuous improvement and broadening service offerings.

#### Key Questions Answered in the Report

What is the expected CAGR of the human duchenne muscular dystrophy treatment market during the forecast period 2024-2032?

How are technological advancements driving the growth of the duchenne muscular dystrophy treatment market?

What role do government support and funding play in advancing duchenne muscular dystrophy research and treatment?

What are the main challenges associated with the high treatment costs of duchenne muscular dystrophy therapies?

How does the limited availability of treatments impact the duchenne muscular dystrophy market?

In what ways are emerging markets presenting growth opportunities for duchenne muscular dystrophy treatments?

How are personalized medicine approaches influencing the future of duchenne muscular dystrophy treatment?

What innovative drug delivery systems are being developed for duchenne muscular dystrophy therapies?

How do collaborative research initiatives drive innovation in the duchenne muscular dystrophy treatment market?

What are the key trends shaping the duchenne muscular dystrophy treatment market, including gene therapy advancements and early intervention?

How do hospitals, retail and online pharmacies, and home care settings contribute to the distribution of duchenne muscular dystrophy treatments?

Which regions are expected to lead the duchenne muscular dystrophy treatment market, and why?

#### Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the human duchenne muscular dystrophy treatment market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the human duchenne muscular dystrophy treatment market.

The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the human duchenne muscular dystrophy treatment industry and its attractiveness.

The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

**Table of Contents:**

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Overview: 8 Major Market
  - 3.1 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Historical Value (2017-2023)
  - 3.2 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
  - 4.1 Key Vendors
  - 4.2 Prospective Leaders
  - 4.3 Niche Leaders
  - 4.4 Disruptors
- 5 Duchenne Muscular Dystrophy (DMD): Disease Overview
  - 5.1 Guidelines and Stages
  - 5.2 Pathophysiology
  - 5.3 Screening and Diagnosis
  - 5.4 Therapy Pathway
- 6 Patient Profile
  - 6.1 Patient Profile Overview
  - 6.2 Patient Psychology and Emotional Impact Factors
  - 6.3 Risk Assessment and Therapy Success Rate
- 7 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Epidemiology Scenario and Forecast - 8 Major Markets
  - 7.1 8MM Epidemiology Scenario Overview (2017-2032)
    - 7.1.1 Prevalence, by Country
      - 7.1.1.1 U.S.
      - 7.1.1.2 U.K.
      - 7.1.1.3 EU4
      - 7.1.1.4 India
      - 7.1.1.5 Japan
    - 7.1.2 Mortality by Country
      - 7.1.2.1 U.S.
      - 7.1.2.2 U.K.

- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Landscape: 8 Major Market\*
- 8.1 Human Duchenne Muscular Dystrophy (DMD) Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Human Duchenne Muscular Dystrophy (DMD) Treatment Market: Product Landscape
- 8.2.1 Analysis by Therapeutic Approaches
- 9 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Human Duchenne Muscular Dystrophy (DMD) Treatment: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter's Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Human Duchenne Muscular Dystrophy (DMD) Treatment Market Segmentation: 8 Major Markets
- 12.1 Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.1.1□Market Overview
- 12.1.2□Molecular-based Therapies
  - 12.1.2.1□Mutation Suppression
  - 12.1.2.2□Exon Skipping
- 12.1.3□Steroid Therapy
- 12.1.4□Other Therapeutic Approaches
- 12.2□Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
  - 12.2.1□Market Overview
  - 12.2.2□Hospitals
  - 12.2.3□Retail and Online Pharmacies
- 12.3□Human Duchenne Muscular Dystrophy (DMD) Treatment Market by End User
  - 12.3.1□Market Overview
  - 12.3.2□Hospitals
  - 12.3.3□Home Care Settings
  - 12.3.4□Clinics
- 12.4□Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Region
  - 12.4.1□Market Overview
  - 12.4.2□United States
  - 12.4.3□EU-4 and the United Kingdom
    - 12.4.3.1□Germany
    - 12.4.3.2□France
    - 12.4.3.3□Italy
    - 12.4.3.4□Spain
    - 12.4.3.5□United Kingdom
  - 12.4.4□Japan
  - 12.4.5□India
- 13□United States Human Duchenne Muscular Dystrophy (DMD) Treatment Market (2017-2032)
  - 13.1□United States Human Duchenne Muscular Dystrophy (DMD) Treatment Market Historical Value (2017-2023)
  - 13.2□United States Human Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast Value (2024-2032)
  - 13.3□United States Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches
    - 13.3.1□Market Overview
    - 13.3.2□Molecular-based Therapies
      - 13.3.2.1□Mutation Suppression
      - 13.3.2.2□Exon Skipping
    - 13.3.3□Steroid Therapy
    - 13.3.4□Other Therapeutic Approaches
  - 13.4□United States Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
    - 13.4.1□Market Overview
    - 13.4.2□Hospitals
    - 13.4.3□Retail and Online Pharmacies
  - 13.5□United States Human Duchenne Muscular Dystrophy (DMD) Treatment Market by End User
    - 13.5.1□Market Overview
    - 13.5.2□Hospitals
    - 13.5.3□Home Care Settings
    - 13.5.4□Clinics
- 14□EU-4 and United Kingdom Human Duchenne Muscular Dystrophy (DMD) Treatment Market (2017-2032)
  - 14.1□EU-4 and United Kingdom Human Duchenne Muscular Dystrophy (DMD) Treatment Market Historical Value (2017-2023)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.2 EU-4 and United Kingdom Human Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches
  - 14.3.1 Market Overview
  - 14.3.2 Molecular-based Therapies
    - 14.3.2.1 Mutation Suppression
    - 14.3.2.2 Exon Skipping
  - 14.3.3 Steroid Therapy
  - 14.3.4 Other Therapeutic Approaches
- 14.4 EU-4 and United Kingdom Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
  - 14.4.1 Market Overview
  - 14.4.2 Hospitals
  - 14.4.3 Retail and Online Pharmacies
- 14.5 EU-4 and United Kingdom Human Duchenne Muscular Dystrophy (DMD) Treatment Market by End User
  - 14.5.1 Market Overview
  - 14.5.2 Hospitals
  - 14.5.3 Home Care Settings
  - 14.5.4 Clinics
- 15 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market
  - 15.1 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market Historical Value (2017-2023)
  - 15.2 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast Value (2024-2032)
  - 15.3 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches
    - 15.3.1 Market Overview
    - 15.3.2 Molecular-based Therapies
      - 15.3.2.1 Mutation Suppression
      - 15.3.2.2 Exon Skipping
    - 15.3.3 Steroid Therapy
    - 15.3.4 Other Therapeutic Approaches
  - 15.4 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
    - 15.4.1 Market Overview
    - 15.4.2 Hospitals
    - 15.4.3 Retail and Online Pharmacies
  - 15.5 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market by End User
    - 15.5.1 Market Overview
    - 15.5.2 Hospitals
    - 15.5.3 Home Care Settings
    - 15.5.4 Clinics
  - 15.6 Japan Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
    - 15.6.1 Market Overview
    - 15.6.2 Hospital and Retail Pharmacies
    - 15.6.3 Government Suppliers
    - 15.6.4 Others
- 16 India Human Duchenne Muscular Dystrophy (DMD) Treatment Market
  - 16.1 India Human Duchenne Muscular Dystrophy (DMD) Treatment Market (2017-2032) Historical Value (2017-2023)
  - 16.2 India Human Duchenne Muscular Dystrophy (DMD) Treatment Market (2017-2032) Forecast Value (2024-2032)
  - 16.3 India Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches
    - 16.3.1 Market Overview
    - 16.3.2 Molecular-based Therapies

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.3.2.1□Mutation Suppression
- 16.3.2.2□Exon Skipping
- 16.3.3□Steroid Therapy
- 16.3.4□Other Therapeutic Approaches
- 16.4□India Human Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
- 16.4.1□Market Overview
- 16.4.2□Hospitals
- 16.4.3□Retail and Online Pharmacies
- 16.5□India Human Duchenne Muscular Dystrophy (DMD) Treatment Market by End User
- 16.5.1□Market Overview
- 16.5.2□Hospitals
- 16.5.3□Home Care Settings
- 16.5.4□Clinics
- 17□Regulatory Framework
- 17.1□Regulatory Overview
- 17.2□US FDA
- 17.3□EU EMA
- 17.4□INDIA CDSCO
- 17.5□JAPAN PMDA
- 17.6□Others
- 18□Patent Analysis
- 18.1□ Analysis by Type of Patent
- 18.2□ Analysis by Publication Year
- 18.3□ Analysis by Issuing Authority
- 18.4□ Analysis by Patent Age
- 18.5□ Analysis by CPC Analysis
- 18.6□ Analysis by Patent Valuation
- 18.7□ Analysis by Key Players
- 19□Clinical Trial Analysis
- 19.1□Analysis by Trial Registration Year
- 19.2□Analysis by Trial Status
- 19.3□Analysis by Trial Phase
- 19.4□Analysis by Therapeutic Area
- 19.5□Analysis by Geography
- 20□Grant Analysis
- 20.1□Analysis by Year
- 20.2□Analysis by Amount Awarded
- 20.3□Analysis by Issuing Authority
- 20.4□Analysis by Grant Product
- 20.5□Analysis by Funding Institute
- 20.6□Analysis by Departments
- 20.7□Analysis by Recipient Organization
- 21□Strategic Initiatives
- 21.1□ Analysis by Partnership Instances
- 21.2□ Analysis by Type of Partnership
- 21.3□ Analysis by Leading Players
- 21.4□ Analysis by Geography

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 22 Supplier Landscape
  - 22.1 Market Share by Top 5 Companies
  - 22.2 Pfizer Inc .
    - 22.2.1 Financial Analysis
    - 22.2.2 Product Portfolio
    - 22.2.3 Demographic Reach and Achievements
    - 22.2.4 Company News and Developments
    - 22.2.5 Certifications
  - 22.3 Sarepta Therapeutics, Inc .
    - 22.3.1 Financial Analysis
    - 22.3.2 Product Portfolio
    - 22.3.3 Demographic Reach and Achievements
    - 22.3.4 Company News and Developments
    - 22.3.5 Certifications
  - 22.4 PTC Therapeutics Inc .
    - 22.4.1 Financial Analysis
    - 22.4.2 Product Portfolio
    - 22.4.3 Demographic Reach and Achievements
    - 22.4.4 Company News and Developments
    - 22.4.5 Certifications
  - 22.5 FibroGen, Inc
    - 22.5.1 Financial Analysis
    - 22.5.2 Product Portfolio
    - 22.5.3 Demographic Reach and Achievements
    - 22.5.4 Company News and Developments
    - 22.5.5 Certifications
  - 22.6 F. Hoffmann-La Roche Ltd
    - 22.6.1 Financial Analysis
    - 22.6.2 Product Portfolio
    - 22.6.3 Demographic Reach and Achievements
    - 22.6.4 Company News and Developments
    - 22.6.5 Certifications
  - 22.7 NS Pharma, Inc .
    - 22.7.1 Financial Analysis
    - 22.7.2 Product Portfolio
    - 22.7.3 Demographic Reach and Achievements
    - 22.7.4 Company News and Developments
    - 22.7.5 Certifications
  - 22.8 Solid Biosciences Inc
    - 22.8.1 Financial Analysis
    - 22.8.2 Product Portfolio
    - 22.8.3 Demographic Reach and Achievements
    - 22.8.4 Company News and Developments
    - 22.8.5 Certifications
  - 22.9 PTC Therapeutics Inc .
    - 22.9.1 Financial Analysis
    - 22.9.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 22.9.3□Demographic Reach and Achievements
- 22.9.4□Company News and Developments
- 22.9.5□Certifications
- 22.10□Nippon Shinyaku Co., Ltd
- 22.10.1□Financial Analysis
- 22.10.2□Product Portfolio
- 22.10.3□Demographic Reach and Achievements
- 22.10.4□Company News and Developments
- 22.10.5□Certifications
- 22.11□Italfarmaco SpA
- 22.11.1□Financial Analysis
- 22.11.2□Product Portfolio
- 22.11.3□Demographic Reach and Achievements
- 22.11.4□Company News and Developmentss
- 22.11.5□Certifications
- 23□Human Duchenne Muscular Dystrophy (DMD) Treatment Market - Distribution Model (Additional Insight)
- 23.1□ Overview
- 23.2□ Potential Distributors
- 23.3□ Key Parameters for Distribution Partner Assessment
- 24□Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25□Payment Methods (Additional Insight)
- 25.1□Government Funded
- 25.2□Private Insurance
- 25.3□Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

\* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

\*\*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Human Duchenne Muscular Dystrophy (DMD) Treatment Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)  
[www.scotts-international.com](http://www.scotts-international.com)